

Form PTO-1449 (modified)		Atty. Docket No.: SONN:065US	Serial No.: 10/521,140
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Eva KONTSEKOVA	
		Filing Date: October 31, 2005	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	Andrä <i>et al.</i> , "Expression of APP in transgenic mice: a comparison of neuron-specific promoters," 17(2):183-190, 1996.
	C17	Araki <i>et al.</i> , "Transgenic rabbits expressing human lipoprotein lipase," <i>Cytotechnology</i> , 33:93-99, 2000.
	C18	Bornemann and Staufenbiel, "Transgenic mouse models of Alzheimer's disease," <i>Ann. NY Acad Sci.</i> , 908:260-266, 2000.
	C19	Braak <i>et al.</i> , "Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry," <i>Acta Neuropathol</i> , 112:389-404, 2006.
	C20	Brinster <i>et al.</i> , "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs," <i>Proc Natl Acad Sci USA</i> , 82:4438-4442, 1985.
	C21	Campbell <i>et al.</i> , "Transgenic models to assess the pathogenic actions of cytokines in the central nervous system," <i>Mol. Psychiatry</i> , 2(2):125-129, 1997.
	C22	Cente <i>et al.</i> , "Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy," <i>European Journal of Neuroscience</i> , 24:1085-1090, 2006.
	C23	Charreau <i>et al.</i> , "Transgenic rats: Technical aspects and models," <i>Transgenic Res.</i> , 5:223-234, 1996.
	C24	Fitzsimons <i>et al.</i> , "Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain," <i>Methods</i> , 28:227-236, 2002.

55377882.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: SONN:065US	Serial No.: 10/521,140
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Eva KONTSEKOVA	
		Filing Date: October 31, 2005	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Glorioso <i>et al.</i> , "HSV as a gene transfer vector for the nervous system," <i>Mol. Biotechnol.</i> , 4(1):87-99, 1995.
	C26	Götz <i>et al.</i> , "Tau and transgenic animal models," <i>Brain Research Reviews</i> , 35:266-286, 2001.
	C27	Hammer <i>et al.</i> , "Production of transgenic rabbits, sheep and pigs by microinjection," <i>Nature</i> , 315(6021):680-683, 1985.
	C28	Härtig <i>et al.</i> , "Hibernation model of tau phosphorylation in hamsters: selective vulnerability of cholinergic basal forebrain neurons – implications for Alzheimer's disease," <i>European Journal of Neuroscience</i> , 25:69-80, 2007.
	C29	Huang <i>et al.</i> , "Neurofibrillary lesions in experimental aluminum-induced encephalopathy and Alzheimer's disease share immunoreactivity for amyloid precursor protein, A $\beta$ , $\alpha_1$ -antichymotrypsin and ubiquitin-protein conjugates," <i>Brain Research</i> , 771:213-220, 1997.
	C30	Ikenaka and Kagawa, "Transgenic systems in studying myelin gene expression," <i>Dev. Neurosci.</i> , 17(3):127-136, 1995.
	C31	Koson <i>et al.</i> , "Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load," <i>European Journal of Neuroscience</i> , 28:239-246, 2008.
	C32	Lewis <i>et al.</i> , "Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein," <i>Nature Genetics</i> , 25:402-405, 2000.
	C33	Quinn, "Neuronal-specific gene expression – the interaction of both positive and negative transcriptional regulators," <i>Prog. Neurobiol.</i> , 50(4):363-379, 1996.
	C34	Richa, "Production of transgenic mice," In: <i>Methods in Molecular Biology</i> , 136:427-434, 2000.
	C35	SantaCruz <i>et al.</i> , "Tau suppression in a neurodegenerative mouse model improves memory function," <i>Science</i> , 309:476-481, 2005.
	C36	Si-Hoe and Murphy, "Production of transgenic rodents by the microinjection of cloned DNA into fertilized one-celled eggs," In: <i>Methods in Molecular Biology</i> , 97:61-100, 2001.
	C37	Vercauteren <i>et al.</i> , "Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer's disease-linked mutations in amyloid precursor protein and presenilin 1," <i>Molecular Brain Research</i> , 132:241-259, 2004.

55377882.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: SONN:065US	Serial No.: 10/521,140
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Eva KONTSEKOVA	
		Filing Date: October 31, 2005	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C38	Wang <i>et al.</i> , "Diverse stabilities of expression in the rat brain from different cellular promoters in a helper virus-free herpes simplex virus type 1 vector system," <i>Human Gene Therapy</i> , 10:1763-1771, 1999.

55377882.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.